<DOC>
	<DOC>NCT01850680</DOC>
	<brief_summary>Primary Objective: To assess the safety and tolerability of a single dose of subcutaneously administered sarilumab in Japanese patients with rheumatoid arthritis (RA) who are receiving concomitant treatment with methotrexate. Secondary Objective: To assess the pharmacokinetic profile of a single subcutaneous (SC) dose of sarilumab in Japanese RA patients.</brief_summary>
	<brief_title>Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Total study duration per patient is up to 88 days 1. Screening: 3 to 28 days 2. Treatment: 1 day 3. Follow-up: 57± 3 days after dosing</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Inclusion criteria: 1. Male or female Japanese who are 20 to 65 years of age 2. Diagnosis of rheumatoid arthritis (RA) ≥ 3 months duration 3. Treated for a minimum of 8 weeks with Methotrexate (MTX) and with a stable dose of MTX (616 mg/week) for a minimum of 4 weeks prior to the screening visit Exclusion criteria: 1. Autoimmune or inflammatory systemic or localized joint disease other than RA 2. Women of a positive pregnancy test 3. Latent or active tuberculosis 4. Prior treatment with antiinterleukin6 (antiIL6) or antiinterleukin6 receptor (IL6R) antagonist 5. Treatment with antiTNF agents, as follows: 1. Etanercept: within 28 days prior to randomization 2. Infliximab, adalimumab, golimumab, certolizumab pegol: within 42 days prior to randomization 6. Received any live, attenuated vaccine within 3 months prior to the randomization visit (eg, varicellazoster, oral polio, rubella vaccines) 7. Significant concomitant illness such as, but not limited to, cardiovascular, renal, neurological, endocrinological, gastrointestinal, hepatobiliary, metabolic, pulmonary or lymphatic disease that would adversely affect the patient's participation in the study. 8. Received surgery within 4 weeks prior to the screening visit or planned surgery during the study 9. History of a systemic hypersensitivity reaction The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>